

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/215876 A3

(51) International Patent Classification:
A61K 47/54 (2017.01) *A61P 3/10* (2006.01)
A61K 38/28 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/US2024/024054

(22) International Filing Date:
11 April 2024 (11.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/495,442 11 April 2023 (11.04.2023) US
63/502,778 17 May 2023 (17.05.2023) US

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
21 November 2024 (21.11.2024)

(72) Inventors: **MALI, Sachitanand**; c/o Eli Lilly and Com-
pany, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).
CHEN, Diao; c/o Eli Lilly and Company, P.O. Box 6288,
Indianapolis, IN 46206-6288 (US). **SPENCER, Ryan, Kel-**
ly; c/o Eli Lilly and Company, P.O. Box 6288, Indianapo-
lis, IN 46206-6288 (US). **STEELE (NEE HALE), Jack,**
Joseph; c/o Eli Lilly and Company, P.O. Box 6288, In-
dianapolis, IN 46206-6288 (US). **LIANG, Jingxin**; c/o
Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN
46206-6288 (US). **SHAKER, Mirna, Ekram, Anwar**; c/
o Eli Lilly and Company, P.O. Box 6288, Indianapolis,
IN 46206-6288 (US). **MAHDAVI, Alborz**; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, IN 46206-6288
(US).

(74) Agent: **WEBER, Thomas, P.** et al.; Eli Lilly and Company,
P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS

(57) Abstract: The disclosure relates to novel compounds that include one or more aromatic boron-containing groups, including di-
boronates, and methods of making the disclosed compounds. The present disclosure further relates to pharmaceutical compositions
comprising the disclosed compounds, and their use in prevention and treatment of diseases and disorders, such as hyperglycemia, type
2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, metabolic syndrome X, or dyslipidemia, diabetes during pregnancy,
pre-diabetes, Alzheimer's disease, MODY 1, MODY 2 or MODY 3 diabetes, mood disorders, and psychiatric disorders.



WO 2024/215876 A3